Corrigendum to “Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells” [Comput. Struct. Biotechnol. J. 16 (2018) 350–360]

• Lea Lough,
• Dan Sherman,
• Manuel Becerra-Flores,
• Deepika Vasudevan,
• Olga Lavinda,
• Eric Ni,
• Hong Wang,
• Hyung Don Ryoo,
• Raoul Tibes,
• Timothy Cardozo

Affiliations

Lea Lough

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Dan Sherman

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Manuel Becerra-Flores

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Deepika Vasudevan

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Olga Lavinda

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Eric Ni

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Hong Wang

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Hyung Don Ryoo

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Raoul Tibes

Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA

Timothy Cardozo

Corresponding author.; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA; Department of Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA